Cancer research meets tick vectors for infectious diseases

0436590 - BC 2015 RIV US eng J - Článek v odborném periodiku
Cabezas-Cruz, A. - Valdés, James J. - de la Fuente, J.
Cancer research meets tick vectors for infectious diseases.
Lancet Infectious Diseases. Roč. 14, č. 10 (2014), s. 916-917. ISSN 1473-3099. E-ISSN 1474-4457
Institucionální podpora: RVO:60077344
Klíčová slova: protective immunity * IgE * responses * mice
Kód oboru RIV: EC - Imunologie
Impakt faktor: 22.433, rok: 2014

Continuous human exploitation of environmental resources and an increase in human outdoor activities have led to more contact with arthropod vectors, promoting an emergence and resurgence of tick-borne pathogens. Clinical trials of cetuximab,1 a monoclonal antibody that inhibits epidermal growth factor receptor used for treatment of metastatic colorectal cancer, have shown that the drug produces more hypersensitivity than expected, with some fatal cases.2 Patients who developed these hypersensitivity reactions were deemed to have pre-existing IgE antibodies specifi c to the alpha-gal present in the variable portion of cetuximab.3
Trvalý link: http://hdl.handle.net/11104/0240373